Ensysce Biosciences Q4 2023 Earnings Report

Ensysce Biosciences EPS Results

• Actual EPS: -$16.95
• Consensus EPS: -$12.90
• Beat/Miss: Missed by -$4.05
• One Year Ago EPS: N/A

Ensysce Biosciences Revenue Results

• Actual Revenue: $0.52 million
• Expected Revenue: $0.53 million
• Beat/Miss: Missed by -$10.00 thousand
• YoY Revenue Growth: N/A

Ensysce Biosciences Announcement Details

• Quarter: Q4 2023
• Date: 3/15/2024
• Time: N/A

Ensysce Biosciences (NASDAQ:ENSC), a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.